Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Revenue projections:

Revenue projections for LLY
Revenue projections for LLY

LLY is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 1.497000
forwardPE 21.418135
debtToEquity 139.015000
earningsGrowth 1.699000
revenueGrowth 0.555000
grossMargins 0.828320
operatingMargins 0.493860
trailingEps 28.170000
forwardEps 44.282570

LLY's current ratio 1.497, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, LLY can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
LLY's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
LLY's high debt-to-equity ratio points to a heavily leveraged company, with more debt than equity in its capital structure. While this can boost growth, it increases financial vulnerability in times of economic difficulty.
With positive growth in both earnings and revenue, LLY is expected to grow its business. These indicators highlight a strong financial outlook, with the company on track for continued expansion and increasing profitability.
LLY's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
With a forward EPS greater than its trailing EPS, LLY is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for LLY
Price projections for LLY

Eli Lilly and Company's price has consistently been situated near the lower end of expected values. This ongoing trend may reflect investor skepticism about the company's growth potential and overall performance.

Insider Transactions:

Insider Transactions for LLY
Insider Transactions for LLY


40 transactions were made to sell LLY shares, with market price of 917.3187454223632.4 transactions to buy LLY took place, with market price at 656.6999969482422 per share.Increased sells at Eli Lilly and Company's current price levels point to a possible decline. If this trend of selling continues, it may signal that the stock's price will face further downward pressure, reflecting investor concerns.

Recommendation changes over time:

Recommendations trend for LLY
Recommendations trend for LLY


Analysts have been favoring Eli Lilly and Company with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning Eli Lilly and Company as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.